ClinicalTrials.gov
public full text
Public Domain
Bioequivalency Study of Fenofibrate 160mg Tablets Under Fasting Conditions
The study was conducted as an open label, balanced, randomised, two-treatment, two-period, two-sequence, single-dose crossover bioavailability study on fenofibrate formulations comparing fenofibrate 160 mg tablets of Ranbaxy Laboratories with Tricor 160 mg tablets in healthy, adult, human subjects under fasting conditions.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fasting Conditions#1085361
- Fed Bioequivalence Study of Fenofibric Acid Versus TriCor® (Fenofibrate)#1093959
- Evaluation of Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin#870269
- Bioequivalence Study of Valsartan 320mg Tablets Under Fed Conditions#979573
- Optimization for Regorafenib in HCC#911847
Record · ID 1163271
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive